1. Home
  2. CTNM vs RELL Comparison

CTNM vs RELL Comparison

Compare CTNM & RELL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • RELL
  • Stock Information
  • Founded
  • CTNM 2009
  • RELL 1947
  • Country
  • CTNM United States
  • RELL United States
  • Employees
  • CTNM N/A
  • RELL N/A
  • Industry
  • CTNM
  • RELL Electronic Components
  • Sector
  • CTNM
  • RELL Technology
  • Exchange
  • CTNM Nasdaq
  • RELL Nasdaq
  • Market Cap
  • CTNM 114.1M
  • RELL 127.4M
  • IPO Year
  • CTNM 2024
  • RELL N/A
  • Fundamental
  • Price
  • CTNM $3.51
  • RELL $9.47
  • Analyst Decision
  • CTNM Strong Buy
  • RELL
  • Analyst Count
  • CTNM 4
  • RELL 0
  • Target Price
  • CTNM $23.75
  • RELL N/A
  • AVG Volume (30 Days)
  • CTNM 83.1K
  • RELL 50.6K
  • Earning Date
  • CTNM 05-14-2025
  • RELL 04-09-2025
  • Dividend Yield
  • CTNM N/A
  • RELL 2.51%
  • EPS Growth
  • CTNM N/A
  • RELL N/A
  • EPS
  • CTNM N/A
  • RELL N/A
  • Revenue
  • CTNM N/A
  • RELL $204,394,000.00
  • Revenue This Year
  • CTNM N/A
  • RELL $9.48
  • Revenue Next Year
  • CTNM N/A
  • RELL $4.10
  • P/E Ratio
  • CTNM N/A
  • RELL N/A
  • Revenue Growth
  • CTNM N/A
  • RELL N/A
  • 52 Week Low
  • CTNM $3.69
  • RELL $7.57
  • 52 Week High
  • CTNM $22.00
  • RELL $15.51
  • Technical
  • Relative Strength Index (RSI)
  • CTNM N/A
  • RELL 53.44
  • Support Level
  • CTNM N/A
  • RELL $9.00
  • Resistance Level
  • CTNM N/A
  • RELL $9.62
  • Average True Range (ATR)
  • CTNM 0.00
  • RELL 0.30
  • MACD
  • CTNM 0.00
  • RELL 0.19
  • Stochastic Oscillator
  • CTNM 0.00
  • RELL 88.19

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About RELL Richardson Electronics Ltd.

Richardson Electronics Ltd provides engineered solutions, power grid, and microwave tubes and related consumables, power conversion, RF and microwave components, high-value flat panel detector solutions, replacement parts, tubes, and service training for diagnostic imaging equipment and customized display solutions. Its products have applications in alternative energy, healthcare, aviation, broadcast, communications, industrial, marine, medical, military, scientific, and semiconductor markets. The company segments include PMT (Power and Microwave Technologies Group), Canvys, (Green Energy Solutions) GES, and Healthcare reportable segments. The company derives the majority of its revenues from the PMT segment.

Share on Social Networks: